Abstract Number: 2238 • 2014 ACR/ARHP Annual Meeting
Exploratory Six Month Phase IIa Study of a Potential Disease Modifying Drug in Patients with OA of the Knee
Background/Purpose: No disease modifying drugs exists to treat osteoarthritis. Recently, a phase II study from Tasmania showed that Zoledronic Acid, a bisphosphonate, has an effect…Abstract Number: 2239 • 2014 ACR/ARHP Annual Meeting
Efficacy of Ketoprofen Lysine Salt in Reducing Inflammation and Pain in Primary Osteoarthritis of the Hand: Preliminary Results of a Retrospective and Prospective Clinical Trial
Background/Purpose: Osteoarthritis (OA) is a common progressive joint disease and a leading cause of musculoskeletal pain and functional disability worldwide. Despite various interventional treatment approaches…Abstract Number: 2240 • 2014 ACR/ARHP Annual Meeting
An Exploratory 4-Week Study of a P2X3 Antagonist AF-219 in the Treatment of Patients with Osteoarthritis (OA) of the Knee
Background/Purpose Targeting P2X3 receptors that mediate the sensitizing effects of ATP released from inflamed and damaged tissues on the primary afferent neurons (PAN) of musculoskeletal…Abstract Number: 2241 • 2014 ACR/ARHP Annual Meeting
Intermittent Analgesic Use and Risk of Pain Exacerbation in Knee Osteoarthritis: A Web Based Case-Crossover Study
Background/Purpose: The pain experienced by osteoarthritis (OA) patients is neither constant nor stable and most patients experience episodes of pain exacerbations or flares. A number…Abstract Number: 2242 • 2014 ACR/ARHP Annual Meeting
Effects of Intraarticular (IA) Corticosteroid Injections on Bone Markers and Endogenous Cortisol in Patients with Knee Osteoarthritis (OA): A Randomized, Double-Blind, Placebo Controlled Trial
Background/Purpose: IA steroids are used to treat knee OA. Little is known about the systemic effect of intraarticular steroid injections on bone or the hypothalamic-pituitary-…Abstract Number: 2243 • 2014 ACR/ARHP Annual Meeting
Comparison Between Two Diclofenac Diethylamine Gel Formulations, 1.16% Vs 2.32%: Is It Only Increasing the Strength of the Active Ingredient Enough?
Background/Purpose Topically applied non-steroidal anti-inflammatory drugs (NSAIDs) can produce clinically effective drug concentrations at a peripheral site, but with low systemic concentrations and thus a…Abstract Number: 2244 • 2014 ACR/ARHP Annual Meeting
Multimedia Patient Education Tool for Patients with Osteoarthritis
Background/Purpose: The use of video modelling in patient education can result in positive patient outcomes including informed decision-making and improved self-management. The purpose of our…Abstract Number: 2245 • 2014 ACR/ARHP Annual Meeting
Characteristics of Conventional Footwear and Their Association with Reductions in Knee Loading with a Flexible Footwear Intervention
Background/Purpose: The peak external knee adduction moment (KAM) as measured through gait analyses has been associated with severity, progression and pain in medial knee osteoarthritis (OA);…Abstract Number: 2246 • 2014 ACR/ARHP Annual Meeting
Reduction of Knee Osteoarthritis Symptoms in a Cohort of Bariatric Surgery Patients
Background/Purpose: Obesity is a modifiable risk factor of knee osteoarthritis (KOA). While medical treatments can have limited beneficial effects, an alternative strategy would target weight…Abstract Number: 2247 • 2014 ACR/ARHP Annual Meeting
Bariatric Surgery Improves Quality of Life in Patients with Osteoarthritis and Obesity Compared to Non-Surgical Weight Loss
Background/Purpose: Numerous studies support obesity as a strong risk factor for development and progression of knee osteoarthritis (OA). The potential benefits of massive weight loss,…Abstract Number: 2248 • 2014 ACR/ARHP Annual Meeting
Clinical Outcomes, Neuropathic Pain and Patient Satisfaction over a 15 Year Period Following Primary Tka: A Repeat-Cross-Sectional Analysis
Background/Purpose Studies evaluating patient-reported long term outcomes (>10 years) after primary TKA are lacking. Moreover, variability in patient satisfaction after TKA has been reported for…Abstract Number: 2249 • 2014 ACR/ARHP Annual Meeting
Criteria for Clinically Important Worsening in Knee and Hip Osteoarthritis
Background/Purpose Clinically important worsening in OA has not been well defined. Validated worsening criteria are important for research but also clinical practice to make informed…Abstract Number: 2250 • 2014 ACR/ARHP Annual Meeting
The Effects of Treatment on Disease Symptoms and Progression of Structural Changes in Knee Osteoarthritis Participants from the Osteoarthritis Initiative Progression Cohort
Background/Purpose: In the perspective of personalized management of osteoarthritis (OA), a clinically relevant concern is the impact of meniscal extrusion on response to treatment. This study evaluated the role…Abstract Number: 2211 • 2014 ACR/ARHP Annual Meeting
Epidemiologic and Clinical Features of Patients with Adult and Juvenile Dermatomyositis, Polymyositis and Inclusion Body Myositis from Myovision, a National Myositis Patient Registry
Background/Purpose: The myositis syndromes are rare systemic autoimmune diseases, little is known about their epidemiology. We describe the demographics and comorbidities of patients in a…Abstract Number: 2212 • 2014 ACR/ARHP Annual Meeting
Serum Adipokines in Dermatomyositis: Correlation with Risk Factors Associated to Cardiovascular Diseases and Metabolic Syndrome
Background/Purpose: Adipokines are a group of cytokines produced by adipose tissue, which include adiponectin, resistin and leptin. The adiponectin has anti-diabetic, anti-inflammatory and anti-atherogenic effects,…
ACR Meeting Abstracts